FDA ends Teva Plan B OTC dominance

The regulator is allowing generic makers room on the OTC contraceptive shelf.

Merck may be near NuvaRing settlement

The drugmaker may be able to settle around 3,800 cases for $100 million.

OPDP not happy with Diclegis promo

OPDP not happy with Diclegis promo


The bad-ad watchdog issued an untitled letter to drugmaker Duchesnay in November.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.